Ascletis Pharma Company Description
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne.
Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 231 |
| CEO | Jinzi Jason Wu |
Contact Details
Address: Building D Hangzhou, 311200 China | |
| Phone | 86 571 8538 9730 |
| Website | ascletis.com |
Stock Details
| Ticker Symbol | ASCLF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG0520K1094 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jinzi Jason Wu Ph.D. | Founder, Chairman and Chief Executive Officer |
| Hejingdao Wu | Senior Vice President of Operations and Executive Director |
| Yuemei Yan | Senior Vice President of Clinical Development Operations |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant and Head of Discovery |
| Dr. George Zhengzhi Hill | Senior Consultant and Chief Medical Advisor |
| John P. Gargiulo M.B.A. | Chief Business Officer |